Biondvax Pharmaceuticals Stock Net Income
BiondVax Pharmaceuticals fundamentals help investors to digest information that contributes to BiondVax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BiondVax Stock. The fundamental analysis module provides a way to measure BiondVax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BiondVax Pharmaceuticals stock.
BiondVax |
BiondVax Pharmaceuticals Company Net Income Analysis
BiondVax Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current BiondVax Pharmaceuticals Net Income | (5.8 M) |
Most of BiondVax Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BiondVax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, BiondVax Pharmaceuticals reported net income of (5.8 Million). This is 101.7% lower than that of the Pharmaceuticals sector and 108.27% lower than that of the Health Care industry. The net income for all United States stocks is 101.02% higher than that of the company.
BiondVax Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BiondVax Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BiondVax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BiondVax Pharmaceuticals by comparing valuation metrics of similar companies.BiondVax Pharmaceuticals is currently under evaluation in net income category among its peers.
BiondVax Fundamentals
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Shares Owned By Insiders | 20.01 % | |||
| Shares Owned By Institutions | 10.69 % | |||
| Number Of Shares Shorted | 4.88 K | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) | |||
| Net Income | (5.8 M) | |||
| Cash And Equivalents | 14.55 M | |||
| Cash Per Share | 2.23 X | |||
| Total Debt | 21.54 M | |||
| Current Ratio | 1.71 X | |||
| Book Value Per Share | (1.96) X | |||
| Cash Flow From Operations | (7.26 M) | |||
| Short Ratio | 0.32 X | |||
| Earnings Per Share | (2.35) X | |||
| Target Price | 39.0 | |||
| Number Of Employees | 33 | |||
| Beta | 2.37 | |||
| Market Capitalization | 4.97 M | |||
| Total Asset | 27.07 M | |||
| Retained Earnings | (115.83 M) | |||
| Working Capital | 12.03 M | |||
| Current Asset | 36.93 M | |||
| Current Liabilities | 1.7 M | |||
| Z Score | -6.6 | |||
| Net Asset | 27.07 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stocks Directory Find actively traded stocks across global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |